Bipolar disorder: candidate drug targets
نویسندگان
چکیده
منابع مشابه
Strategies to Find Candidate Genes for Bipolar Disorder
Sir. Linkage studies have been revealing many new linkage loci not supporting previous regions of interest in the development of bipolar disorder. In addition, a number of association studies failed to get continuous repli-cations as well as family based association studies in bi-polar disorders. 1 Moreover, 5-HTTLPR and brain-derived neurotrophic factor (BDNF) promoter polymorphisms are now fo...
متن کاملPolypharmacy in Bipolar Disorder - a Focus on Drug - Drug Interactions
Background: Drug-drug interactions (DDI) are actually quite commonplace and are responsible for considerable patient morbidity and mortality. The two major varieties of DDI are pharmacodynamic and pharmacokinetic interactions (cytochrome P450 system). Conditions such as bipolar disorder (with many psychiatric and somatic comorbidities) are complex symptom clusters and bipolar patients may need ...
متن کاملCandidate drug targets for prevention or modification of epilepsy.
Epilepsy is a prevalent neurological disorder afflicting nearly 50 million people worldwide. The disorder is characterized clinically by recurrent spontaneous seizures attributed to abnormal synchrony of brain neurons. Despite advances in the treatment of epilepsy, nearly one-third of patients are resistant to current therapies, and the underlying mechanisms whereby a healthy brain becomes epil...
متن کاملBipolar Disorder 3 Treatment of bipolar disorder
We review recent developments in the acute and long-term treatment of bipolar disorder and identify promising future routes to therapeutic innovation. Overall, advances in drug treatment remain quite modest. Antipsychotic drugs are effective in the acute treatment of mania; their efficacy in the treatment of depression is variable with the clearest evidence for quetiapine. Despite their widespr...
متن کاملSMRI contributions to drug development for schizophrenia and bipolar disorder.
The development of better drugs for the treatment of schizophrenia and bipolar disorder has been the primary goal of the Stanley Medical Research Institute (SMRI) since its inception. The first SMRI treatment trial was funded in 1992, and since then, approximately 200 additional trials have been funded. The SMRI strategy has been to focus resources on approaches not being widely pursued by the ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Mount Sinai Journal of Medicine: A Journal of Translational and Personalized Medicine
سال: 2008
ISSN: 0027-2507,1931-7581
DOI: 10.1002/msj.20042